BIOMAT Database Logo BIOMAT Database Logo

Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome. 2022

Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, 81310, Istanbul, Turkey.

There are limited data about humoral response to vaccine in Behçet's syndrome (BS). We compared SARS-CoV-2 antibody response after two doses of inactivated (Sinovac/CoronaVac) or mRNA (Pfizer/BioNTech) vaccines in patients with BS and healthy controls (HCs). We studied 166 (92M/74F) patients with BS (mean age: 42.9 ± 9.6 years) and 165 (75M/90F) healthy controls (mean age: 42.4 ± 10.4 years), in a single-center cross-sectional design between April 2021 and October 2021. A total of 80 patients with BS and 89 HCs received two doses of CoronaVac, while 86 patients with BS and 76 HCs were vaccinated with BioNTech. All study subjects had a negative history for COVID-19. Serum samples were collected at least 21 days after the second dose of the vaccine. Anti-spike IgG antibody titers were measured quantitatively using a commercially available immunoassay method. We found that the great majority in both patient and HC groups had detectable antibodies after either CoronaVac (96.3% vs 100%) or BioNTech (98.8% vs 100%). Among those vaccinated with CoronaVac, BS patients had significantly lower median (IQR) titers compared to HCs [36.5 (12.5-128.5) vs 102 (59-180), p < 0.001]. On the other hand, antibody titers did not differ among patients with BS and HCs who were vaccinated with BioNTech [1648.5 (527.0-3693.8) vs 1516.0 (836.3-2599.5), p = 0.512). Among different treatment regimen subgroups in both vaccine groups, those who were using anti-TNF-based treatment had the lowest antibody titers. However, the difference was statistically significant only among those vaccinated with CoronaVac. Among patients vaccinated with BioNTech, there was no statistically significant difference between different treatment regimen groups. Compared to inactivated COVID-19 vaccine, mRNA-based vaccine elicited higher antibody titers among BS patients. Only in the CoronaVac group, patients especially those using anti-TNF agents were found to have low titers compared to healthy subjects. BS patients vaccinated with BioNTech were found to have similar seroconversion rates and antibody levels compared to healthy controls. Further studies should assess whether the low antibody titers are associated with diminished protection against COVID-19 in both vaccine groups.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000079424 Tumor Necrosis Factor Inhibitors Compounds or agents that bind to and inhibit the synthesis or activity of TUMOR NECROSIS FACTOR-alpha. Such agents are used to treat inflammatory bowel diseases and other inflammatory diseases. TNF Antagonist,TNF Blocker,TNF Inhibitor,Tumor Necrosis Factor Antagonist,Tumor Necrosis Factor Blocker,Tumor Necrosis Factor Inhibitor,Tumor Necrosis Factor-a (TNF-a) Antagonist,Tumor Necrosis Factor-a (TNF-a) Blocker,Tumor Necrosis Factor-a (TNF-a) Inhibitor,TNF Antagonists,TNF Blockers,TNF Inhibitors,Tumor Necrosis Factor Antagonists,Tumor Necrosis Factor Blockers,Tumor Necrosis Factor-a (TNF-a) Antagonists,Tumor Necrosis Factor-a (TNF-a) Blockers,Tumor Necrosis Factor-a (TNF-a) Inhibitors,Antagonist, TNF,Antagonists, TNF,Blocker, TNF,Blockers, TNF,Inhibitor, TNF,Inhibitors, TNF
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody

Related Publications

Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
Antibody responses to inactivated SARS-CoV-2 vaccine in peritoneal dialysis patients.
May 2022, Seminars in dialysis,
Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.
May 2021, The New England journal of medicine,
Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
June 2021, Nature communications,
Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
Acute Coronary Syndrome After Inactivated SARS-COV-2 Vaccine.
January 2022, International heart journal,
Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients.
January 2022, Frontiers in microbiology,
Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.
November 2023, Vaccine,
Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
Fever after Vaccination against SARS-CoV-2 with mRNA-Based Vaccine Associated with Higher Antibody Levels during 6 Months Follow-Up.
March 2022, Vaccines,
Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?
August 2022, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy,
Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
May 2024, Scientific reports,
Ayse Ozdede, and Okan Kadir Nohut, and Zeynep Atli, and Yeşim Tuyji Tok, and Sabriye Guner, and Erkan Yilmaz, and Didar Ucar, and Ugur Uygunoglu, and Vedat Hamuryudan, and Emire Seyahi
SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals.
April 2022, Vaccines,
Copied contents to your clipboard!